Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Historical evolution of human anthrax from occupational disease to potentially global threat as bioweapon.

D'Amelio E, Gentile B, Lista F, D'Amelio R.

Environ Int. 2015 Dec;85:133-46. doi: 10.1016/j.envint.2015.09.009. Review.

PMID:
26386727
2.

Designing inhibitors of anthrax toxin.

Nestorovich EM, Bezrukov SM.

Expert Opin Drug Discov. 2014 Mar;9(3):299-318. doi: 10.1517/17460441.2014.877884. Review.

3.

Assessment of medical reserve corps volunteers' emergency response willingness using a threat- and efficacy-based model.

Errett NA, Barnett DJ, Thompson CB, Tosatto R, Austin B, Schaffzin S, Ansari A, Semon NL, Balicer RD, Links JM.

Biosecur Bioterror. 2013 Mar;11(1):29-40. doi: 10.1089/bsp.2012.0047.

4.

An overview of anthrax infection including the recently identified form of disease in injection drug users.

Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ.

Intensive Care Med. 2012 Jul;38(7):1092-104. doi: 10.1007/s00134-012-2541-0. Review.

5.

Determinants of emergency response willingness in the local public health workforce by jurisdictional and scenario patterns: a cross-sectional survey.

Barnett DJ, Thompson CB, Errett NA, Semon NL, Anderson MK, Ferrell JL, Freiheit JM, Hudson R, Koch MM, McKee M, Mejia-Echeverry A, Spitzer J, Balicer RD, Links JM.

BMC Public Health. 2012 Mar 7;12:164. doi: 10.1186/1471-2458-12-164.

6.

Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys.

Chabot DJ, Joyce J, Caulfield M, Cook J, Hepler R, Wang S, Vietri NJ, Ruthel G, Shoop W, Pitt L, Leffel E, Ribot W, Friedlander AM.

Vaccine. 2012 Jan 20;30(5):846-52. doi: 10.1016/j.vaccine.2011.12.010.

PMID:
22172509
7.

Anthrax infection.

Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1333-41. doi: 10.1164/rccm.201102-0209CI. Review.

8.

Recognition of community-acquired anthrax: has anything changed since 2001?

Stephens MB, Marvin B.

Mil Med. 2010 Sep;175(9):671-5.

PMID:
20882930
9.

Public health and environmental response to the first case of naturally acquired inhalational anthrax in the United States in 30 years: infection of a new york city resident who worked with dried animal hides.

Nguyen TQ, Clark N; 2006 NYC Anthrax Working Group., Karpati A, Goldberg A, Paykin A, Tucker A, Baker A, Almiroudis A, Fine A, Tsoi B, Aston C, Berg D, Weiss D, Connelly E, Beaudry G, Weisfuse I, Durrah JC, Prudhomme J, Leighton J, Ackelsberg J, Mahoney K, Van Vynck L, Lee L, Moskin L, Layton M, Wong M, Raphael M, Robinson M, Phillips M, Jones M, Jeffery N, Nieves R, Slavinski S, Mullin S, Beatrice ST, Balter S, Blank S, Frieden T, Keifer M, Rosenstein N, Diaz P, Clark T, Compton H, Daloia J, Cardarelli J, Norrell N, Horn E, Jackling S, Bacon C, Glasgow E, Gomez T, Baltzersen RA, Kammerdener C, Margo-Zavazky D, Colgan J, Pulaski P.

J Public Health Manag Pract. 2010 May-Jun;16(3):189-200. doi: 10.1097/PHH.0b013e3181ca64f2.

PMID:
20357604
10.

The role of anthrolysin O in gut epithelial barrier disruption during Bacillus anthracis infection.

Bishop BL, Lodolce JP, Kolodziej LE, Boone DL, Tang WJ.

Biochem Biophys Res Commun. 2010 Apr 2;394(2):254-9. doi: 10.1016/j.bbrc.2010.02.091.

11.

Protecting against future shock--inhalational anthrax.

Nabel GJ.

N Engl J Med. 2009 Jul 9;361(2):191-3. doi: 10.1056/NEJMe0903259. No abstract available.

PMID:
19587345
12.

Evaluation of Gram-positive rod surveillance for early anthrax detection.

Mlynarski D, Rabatsky-Ehr T, Petit S, Purviance K, Mshar PA, Begier EM, Johnson DG, Hadler JL; Connecticut Bioterrorism Field Epidemiology Response Team..

Epidemiol Infect. 2009 Nov;137(11):1623-30. doi: 10.1017/S0950268809002581.

PMID:
19397835
13.

A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.

Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, Twenhafel NA, Ivins BE, Kellogg MD, Webster WM, Wright ME, Friedlander AM.

J Infect Dis. 2009 Feb 1;199(3):336-41. doi: 10.1086/596063.

14.

Bioterrorism and the anaesthesiologist's perspective.

Dichtwald S, Weinbroum AA.

Best Pract Res Clin Anaesthesiol. 2008 Sep;22(3):477-502. Review.

PMID:
18831299
15.

Modeling the incubation period of inhalational anthrax.

Wilkening DA.

Med Decis Making. 2008 Jul-Aug;28(4):593-605. doi: 10.1177/0272989X08315245.

PMID:
18556642
16.

Pediatric anthrax: implications for bioterrorism preparedness.

Bravata DM, Wang E, Holty JE, Lewis R, Wise PH, Nayak S, Liu H, McDonald KM, Owens DK.

Evid Rep Technol Assess (Full Rep). 2006 Aug;(141):1-48. Review.

17.

Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route.

Cleret A, Quesnel-Hellmann A, Vallon-Eberhard A, Verrier B, Jung S, Vidal D, Mathieu J, Tournier JN.

J Immunol. 2007 Jun 15;178(12):7994-8001.

18.

Public health and bioterrorism: renewed threat of anthrax and smallpox.

Wallin A, Luksiene Z, Zagminas K, Surkiene G.

Medicina (Kaunas). 2007;43(4):278-84. Review.

19.

Bioterrorism-related inhalational anthrax: can extrapolated adult guidelines be applied to a pediatric population?

Place RC, Hanfling D, Howell JM, Mayer TA.

Biosecur Bioterror. 2007 Mar;5(1):35-42.

PMID:
17437350
20.
Items per page

Supplemental Content

Loading ...
Support Center